SMSarah McBane

Sarah McBane

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sarah McBane has a total of 74 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Menopausal Hormone Therapy: A Narrative Review of Contemporary Evidence

    by Shannon W. Finks, Nicole E. Cieri‐Hutcherson, Veronica Vernon, Sarah E. McBane

    Menopausal hormone therapy (MHT) remains the most effective treatment for vasomotor and genitourinary symptoms of menopause; however, its use declined sharply following the publication of the Women's Health Initiative (WHI). Misinterpretation and limitations of WHI findings have led to persistent misconceptions and underutilization of MHT. This expert opinion aims to clarify evidence‐based approaches to MHT selection, safety, and individualized management. This article was informed by a structured narrative review of the literature with the aim to contextualize evolving pharmacotherapeutic evidence and inform clinical decision‐making. PubMed/MEDLINE, Embase, and the Cochrane Library were searched for studies published from 2002 to 2025. Key opinion statements were developed through expert consensus and paired with a synthesis of contemporary evidence to form recommendations. A critical appraisal of the WHI and subsequent analyses demonstrates that age at initiation, timing since menopause, and hormone formulation utilized significantly influence outcomes. Contemporary data support the preferential use of transdermal estradiol due to its lower risk of venous thromboembolism and favor oral micronized progesterone (MP) over synthetic progestogens when endometrial protection is required. Individualization of therapy—including formulation, route, and dosing—is emphasized as central to optimizing the benefit–risk profile. Current evidence supports the safety of low‐dose vaginal estrogen for genitourinary syndrome of menopause including in cancer survivors. Further evidence highlights potential cardiovascular and cognitive benefits when MHT is initiated within 10 years of menopause. Clinicians caring for menopausal women should promote individualized, evidence‐based MHT through education, therapeutic selection, shared decision making, and ongoing monitoring. Continued research is needed to refine dosing targets, evaluate long‐term preventive outcomes, and expand evidence for modern formulations beyond WHI‐era therapies. Ultimately, MHT should be viewed not as a one‐size‐fits‐all therapy, but as a personalized, evidence‐informed strategy that supports the health and quality of life of menopausal women.


  • Education and Training of Today's Clinical Pharmacist

    by Sharon See, Branden D. Nemecek, Sheila M. Allen, Ijeoma Agada, Shubha Bhat, Eliza Dy‐Boarman, Michelle Fravel, Susan Hamblin, Lauren Hynicka, Kristi Kelley, et al.

    Today's clinical pharmacists have graduated from a doctor of pharmacy professional degree program, completed residency training, and obtained board certification. Their foundational education consists of an extensive didactic and experiential curriculum with a strong focus on pharmacology and pharmacotherapeutics. The credit hours devoted to pharmacology and pharmacotherapeutics are substantially greater than those of other health care professional degree programs. When combined with the clinical learning acquired through formal, postgraduate residency training, clinical pharmacists are well prepared to address medication therapy problems and serve as essential members of interprofessional health care teams. This commentary details the education and training of clinical pharmacists and how these compare with other members of the health care team and concludes that clinical pharmacists are uniquely positioned to optimize medication outcomes.


  • Pharmacotherapy of Chronic Neuropsychiatric Conditions During Pregnancy

    by Sarah M. Westberg, Regina Arellano, Nicole E. Cieri-Hutcherson, Natalie T. Heinrich, Alexandra M. Herman, Nicole M. Lodise, Sarah McBane, Theresa U. Ofili, Niamh O’grady, Kjersten H. Sankey


  • 2023 update to the American College of Clinical Pharmacy Pharmacotherapy Didactic Curriculum Toolkit

    by Denise M. Kolanczyk, Jessica R. Merlo, Bridget Bradley, Alexander H. Flannery, Caitlin M. Gibson, Sarah McBane, Julie A. Murphy, Jacob M. Noble, Melissa B. Noble, Hunter M. Patton, et al.

    The American College of Clinical Pharmacy (ACCP) Pharmacotherapy Didactic Curriculum Toolkit has been used by colleges and schools of pharmacy as a guide for curricular development and revisions since its inaugural publication in 2009. The toolkit was last revised and updated by the 2019 Publications Committee. The 2023 ACCP Publications Committee was charged with reviewing the 2019 Update to the ACCP Pharmacotherapy Didactic Curriculum Toolkit to determine any necessary revisions/updates. The committee revised tier classifications, shifting the focus of the 2023 toolkit to content within the Pharm.D. curriculum. Multiple literature sources were reviewed to assess conditions for inclusion in the 2023 toolkit, and external feedback was solicited from various practice disciplines. All topics were voted on by a simple majority rule during virtual meetings or by electronic votes. There are a total of 231 topics in the 2023 toolkit, a decrease of 77 (23.2%) from the 2019 edition. Topics in each tier are as follows: 68 as tier 1 (29%), 111 as tier 2 (48%), and 52 as tier 3 (23%). Although some topics were removed completely, others were combined with other line items or revised, which may further minimize curricular overload. Similar to the 2016 and 2019 toolkits, many tier 2 topics remain in the 2023 toolkit, emphasizing the continued need for additional training through postgraduate residencies or fellowships (or “on‐the‐job” equivalent experiences), board certifications, and various certificate training programs. The 2023 ACCP Pharmacotherapy Didactic Curriculum Toolkit is designed to assist individual faculty and colleges and schools of pharmacy with curricular development and revisions. It will continue to be reviewed every 3 years to identify needed revisions on the basis of the pharmacist's evolving role, advances in therapeutics and pharmacy practice, and changes to accreditation standards and recognized professional competencies.


  • Open Access

    Overview of implementation and learning outcomes of simulation in pharmacy education

    by Sarah McBane, Prasannaraddi Alavandi, Sheila Allen, Angela Bingham, Yen Dang, Abigail Elmes, Julianne M. Fallon, Alexandra Herman, Jenna Januszka, Apryl N. Peddi, et al.

    Simulation, an educational, assessment, and research technique used to mimic real‐world situations, is increasingly used in pharmacy education. The most‐used simulation methods include high‐fidelity simulation (HFS), low‐fidelity simulation (LFS), standardized patients, and game‐based simulation. A common element of simulation is its ability to offer learners the chance to practice a skill or acquire knowledge in a safe and accessible space. Simulation methods differ in key aspects, including cost and other resource investment as well as ideal venue for use in education. HFS provides a more realistic simulation environment than LFS but is typically more expensive. Standardized patients offer learners the opportunity to engage with a live person but may elicit greater variability in responses to learners' input than HFS. Computer‐based simulation uses technology to supply a wide variety of learning opportunities; however, it may require the use of proprietary software and devices. Despite widespread use, literature describing learning outcomes of simulation in pharmacy education is limited. Some existing reports with positive findings have focused on learner satisfaction with or perceived benefit of simulation activities. The few existing publications summarizing changes in skills or knowledge demonstrate a positive impact. Simulation is a promising modality for educating pharmacy students and residents; however, more data summarizing the benefit of learning outcomes are needed.


  • Peripartum Pharmacotherapy: A Pharmacist’s Guide

    by Kylie N. Barnes, Lauren D. Leader, Nicole E. Cieri-Hutcherson, Julie Kelsey, Mary F. Hebert, Lamis R. Karaoui, Sarah McBane

    Complications throughout the peripartum period may be caused by preexisting conditions or pregnancy-induced conditions and may alter pharmacotherapy management. Pharmacotherapy management during late pregnancy and delivery requires careful consideration due to changing hormones, hemodynamic status, and pharmacokinetics, and concerns for potential maternal and/or fetal morbidity. Increased maternal and fetal monitoring are often required and may lead to therapy changes. Pharmacists, as key members of the interprofessional team, can contribute essential perspective to the management of postpartum pharmacotherapy through assessment and recommendation of appropriate and judicious use of medications.


  • Educational Outcomes Necessary to Enter Pharmacy Residency Training

    by Elizabeth Kelly Hester, Sarah E. McBane, Michael B. Bottorff, Tristan A. Carnes, Kamila Dell, Michael J. Gonyeau, Angelo J. Greco, Karen J. McConnell, Debra J. Skaar, Michele Y. Splinter, et al.

    It is the position of the American College of Clinical Pharmacy (ACCP) that formal postgraduate residency training, or equivalent experience, is required to enter direct patient care practice. Therefore, it is important to align professional degree educational outcomes with the knowledge, skills, and attitudes needed to enter residency training. This position statement addresses the outcomes necessary in the professional degree program curriculum to ensure the ability of pharmacy graduates to transition effectively into postgraduate year one residency training. Five key outcome areas are identified: communication, direct patient care, professionalism, research, and practice management. The position statement examines how performance in each of the five outcome areas should be addressed by professional degree programs. The ACCP believes that for the student to achieve the clinical proficiency necessary to enter residency training, the professional degree program should emphasize, assess, and provide adequate opportunities for students to practice: communication with patients, caregivers, and members of the health care team in direct patient care environments; provision of direct patient care in a wide variety of practice settings, especially those involving patient‐centered, team‐based care; professionalism under the supervision and guidance of faculty and preceptors who model and teach the traits of a health care professional; application of principles of research that engender an appreciation for the role of research and scholarship in one's professional development; and application of practice management, including documentation of direct patient care activities that affect drug‐related outcomes.